From strategy to execution and implementation, company modernizes its real estate portfolio to achieve new strategic goals
Client story
17 October 2023
Biopharma company reshapes its global footprint
Your browser doesn't support speech synthesis.
Listen to article •
: 1 sec
Spotlight
A refreshed portfolio strategy bridges legacy and innovation
Size
15 million sq. ft.
Value
22 total transactions since 2020
With a legacy of innovation since the 1800s, a global biopharma company rallies around its mission to bring life-saving medicines to people with serious diseases. Over the last several years, that has meant consolidating its broad product portfolio to more focused solutions while expanding into promising new therapeutic areas, including cell and gene therapy.
As the organization began reinventing itself as a cutting-edge biopharma company, leadership realized that it also needed to rethink its real estate footprint.
Reinventing legacy real estate for a new future
The company’s portfolio included many legacy facilities that did not support the new strategic focus. In some cities, the company faced a surplus of locations due to mergers and acquisitions or operating structure changes. Additionally, older campus environments made it difficult to attract the best and brightest talent. At the same time, the company needed to invest in new manufacturing facilities in select geographies to achieve growth in the cell and gene therapy market.
It was time to reimagine the real estate portfolio for the future. The company needed offices, research centers and manufacturing facilities in the right locations to attract talent, support its supply chain and manage cost pressures. For help implementing its new vision, the company turned to JLL.
A real estate portfolio designed for innovation
The company continues to make progress in rolling out its real estate strategy, designed to support its mission to drive scientific breakthroughs. Since 2020, JLL has been instrumental in the transition of more than 20 of the company’s global real estate assets, including the sale of several large and complex campuses. The team also helped revitalize a number of legacy campuses, allowing the company to bolster the communities where it does business.
With a large team providing support across the extensive biopharma real estate portfolio and facilities for several years, JLL has connected pillars across the organization, offered historical knowledge and helped maintain a culture of excellence in facilities management. Additionally, JLL’s expertise in sustainability, workplace strategy, and diversity, equity and inclusion has inspired the company’s real estate team as it looks to the future.
Looking ahead to the future of biopharma
The right real estate locations for attracting talent and managing global supply chains will continue to shift as science evolves and new therapies emerge. As the biopharma company reshapes its global real estate footprint, JLL remains a preferred partner to support location strategy and site selection, divestitures, and ongoing management of its existing portfolio and facilities. By supporting where the company is heading, JLL is helping it to fulfill its mission to deliver life-saving medicines to patients.
Ready to take a fresh look at your own portfolio strategy? Contact us today.